11.2022 - 02.2026

Pharmacology for precision medicine in psychotic mood disorders

WP5 focuses on pharmacogenetics applied to mood and psychotic disorders, with the aim of making treatments more targeted and effective. Activities include the identification of genetic and non-genetic markers associated with response, remission and resistance, analyzing large clinical cohorts and biobanks. Genomic, clinical, sociodemographic and environmental data are integrated. Among the focuses are the study of variants that influence the metabolism of antidepressants, the impact of medical comorbidities, polyformisms and polygeic scores on therapeutic outcomes. The use of advanced statistical methods allows us to build predictive models that combine genetic and non-genetic variables. The transdiagnostic approach allows us to identify common and specific factors that influence multiple disorders, improving patient stratification. The expected results aim to support clinical decisions, reduce adverse events and improve the personalization of care.

Early stratification with risk of non-response/resistance or lack of remission in depression, bipolar disorder and psychosis; decision support that can be integrated into electronic medical records; targeted use of pharmacogenetic tests (e.g. CYP2C19/CYP2D6) and management of interactions; optimisation of dose, sequence and therapeutic combinations; personalised follow-up and monitoring programmes; evidence-based care pathways; reduction of adverse events, treatment response times and costs; basis for the identification of new indications for existing drugs and for the development of public health tools.

Settori Scientifico Disciplinari

MED/25  PSYCHIATRY

Spoke 5 : Mood and Psychosis